Innate Pharma S.A.
Innate Pharma S.A. (IPHYF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IPHYF · as of Jun 9, 2026
Key Statistics
Explore Innate Pharma S.A. Data
iphyf stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 100.0%
Competitors & Peers
iphyf competitorsIPHYF
AAWH
BRIBF
BXPHF
HOFBF
JWCTFStock Performance
Full HistoryAbout Innate Pharma S.A.
Innate Pharma S.A. a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily …
what is innate pharma s.a. · iphyf stock overview · innate pharma s.a. company profile · who is innate pharma s.a. ceo · iphyf OTC · innate pharma s.a. headquarters · innate pharma s.a. business segments
About Stock Overview & Key Data
Innate Pharma S.A. (IPHYF) is a Healthcare company in the Biotechnology industry, listed on OTC since Jun 9, 2015. As of the latest trading session, IPHYF stock price is $2.25, with a market capitalization of $211.3M. The stock has returned +55.17% over the past 12 months and +4.65% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Innate Pharma S.A. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Innate Pharma S.A. reported revenue of $2.8M and net income of -$49.2M. For detailed data — including Innate Pharma S.A. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Innate Pharma S.A. (IPHYF) stock price is $2.25. The stock is traded on OTC under the ticker symbol IPHYF. The 52-week range is $1.31 – $2.25.